| Literature DB >> 33609251 |
Shankar Balasubramanian1, Bhushan Chittawadagi2, Shivanshu Misra2, Parthasarathi Ramakrishnan2, Palanivelu Chinnusamy2.
Abstract
Thoracolaparoscopic esophagectomy (TLE) for carcinoma esophagus has better short-term outcomes compared to open esophagectomy. The precise role of robot-assisted laparoscopic esophagectomy (RALE) is still evolving. Single center retrospective analysis of TLE and RALE performed for carcinoma esophagus between January 2015 and September 2018. Propensity score matching was done between the groups for age, gender, BMI, ASA grade, tumor location, neoadjuvant therapy, the extent of surgical resection (Ivor Lewis or McKeown's), histopathological type (squamous cell carcinoma or adenocarcinoma), clinical T and N stages. The primary outcome parameter was lymph node yield. Secondary outcome parameters were resection margin status, duration of surgery, blood loss, conversion to open procedure, length of hospital stay, length of ICU stay, complications, 90-day mortality and cost. There were 90 patients in TLE and 25 patients in RALE group. After propensity matching, there were 22 patients in each group. The lymph node yield was similar in both the groups (23.95 ± 8.23 vs 22.73 ± 11.63; p = 0.688). There were no conversions or positive resection margins in either group. RALE was associated with longer operating duration (513.18 ± 91.23 min vs 444.77 ± 64.91 min; p = 0.006) and higher cost ($5271.75 ± 456.46 vs $4243.01 ± 474.64; p < 0.001) than TLE. Both were comparable in terms of blood loss (138.86 ± 31.20 ml vs 133.18 ± 34.80 ml; p = 0.572), Clavien-Dindo grade IIIa and above complications (13.64% vs 9.09%; p = 0.634), hospital stay (12.18 ± 6.35 days vs 12.73 ± 7.83 days; p = 0.801), ICU stay (4.91 ± 5.22 days vs 4.77 ± 4.81 days; p = 0.929) and mortality (0 vs 4.55%; p = 0.235). RALE is comparable to TLE in terms of short-term oncological and perioperative outcomes except for longer operating duration when performed for carcinoma esophagus. RALE is costlier than TLE.Entities:
Keywords: Carcinoma; Esophagectomy; Esophagus; Laparoscopy; Robot; Thoracoscopy
Mesh:
Year: 2021 PMID: 33609251 PMCID: PMC7896161 DOI: 10.1007/s11701-021-01211-w
Source DB: PubMed Journal: J Robot Surg ISSN: 1863-2483
Fig. 1Port position for the thoracic phase of TLE. a–Camera port in 7th ICS; b–right hand working port in 5th ICS; c–left hand working port in 9th ICS; d–optional 5 mm port in 11th ICS
Fig. 2Port position for the thoracic phase of RALE. a–Camera port in 6th ICS; b–robotic first arm in 3rd ICS; c–robotic second arm in 8th ICS; d–robotic third arm (optional) in 10th ICS
Fig. 3Port position for the abdominal phase of TLE. a–Supra umbilical camera port; b–right hand working port in left mid clavicular line; c–left hand working port in right mid clavicular line; d–epigastric port for liver retraction; e–port for gastric retraction in left anterior axillary line
Fig. 4Port position for the abdominal phase of RALE. a–Umbilical camera port; b–robotic first arm in left mid clavicular line; c–robotic second arm in right mid clavicular line; d–robotic third arm in right anterior axillary line; e–laparoscopic 12 mm assistant port
Baseline demographic and tumor characteristics
| Parameter | TLE ( | RALE ( | TLEm ( | RALEm ( | ||
|---|---|---|---|---|---|---|
Age (years) Mean ± SD | 64.51 ± 12.21 | 61.88 ± 9.83 | 0.324 | 59.27 ± 11.60 | 60.91 ± 9.31 | 0.609 |
| Males | 52 (57.78%) | 17 (68%) | 0.351 | 12 (57.14%) | 14 (63.64%) | 0.539 |
BMI (kg/m2) Mean ± SD | 18.22 ± 2.14 | 20.32 ± 4.24 | 0.001* | 18.91 ± 2.07 | 19.07 ± 2.08 | 0.797 |
| ASA grade | ||||||
| 1 | 2 (2.22%) | 0 | 0.586 | 2 (9.09%) | 0 | 0.211 |
| 2 | 59 (65.56%) | 16 (64%) | 15 (68.18%) | 15 (68.18%) | ||
| 3 | 29 (32.22%) | 9 (36%) | 5 (22.73%) | 7 (31.82%) | ||
| Tumor location | ||||||
| Upper 3rd | 1 (1.11%) | 0 | 0.209 | 1 (4.55%) | 0 | 0.560 |
| Middle 3rd | 14 (15.56%) | 7 (28%) | 5 (22.73%) | 6 (27.27%) | ||
| Lower 3rd | 16 (17.78%) | 7 (28%) | 4 (18.18%) | 6 (27.27%) | ||
| GEJ | 59 (65.56%) | 11 (44%) | 12 (54.55%) | 10 (45.45%) | ||
| Histology | ||||||
| SCC | 58 (64.44%) | 19 (76%) | 0.267 | 17 (77.27%) | 17 (77.27%) | 1.000 |
| AC | 32 (35.56%) | 6 (24%) | 5 (22.73%) | 5 (22.73%) | ||
| Tumor grade | ||||||
| 1 | 0 | 2 (8%) | 0.017* | 0 | 2 (9.09%) | 0.120 |
| 2 | 86 (95.56%) | 20 (80%) | 21 (95.45%) | 17 (77.27%) | ||
| 3 | 4 (4.44%) | 3 (12%) | 1 (4.55%) | 3 (13.64%) | ||
| cT | ||||||
| 1/2 | 19 (21.11%) | 6 (24%) | 0.759 | 7 (31.82%) | 6 (27.27%) | 0.741 |
| 3/4 | 71 (78.89%) | 19 (76%) | 15 (68.18%) | 16 (72.73%) | ||
| cN | ||||||
| N0 | 36 (40%) | 10 (40%) | 1.000 | 10 (45.45%) | 9 (40.91%) | 0.761 |
| N+ | 54 (60%) | 15 (60%) | 12 (54.55%) | 13 (59.09%) | ||
| Neoadjuvant therapy | ||||||
| Yes | 51 (56.67%) | 18 (72%) | 0.159 | 19 (86.36%) | 17 (77.27%) | 0.432 |
| No | 39 (43.33%) | 7 (28%) | 3 (13.64%) | 5 (22.73%) | ||
| Surgery | ||||||
| McKeown | 47 (52.22%) | 15 (60%) | 0.489 | 12 (54.55%) | 14 (63.64%) | 0.539 |
| Ivor Lewis | 43 (47.78%) | 10 (40%) | 10 (45.45%) | 8 (36.36%) | ||
| Anastomosis | ||||||
| Hand sewn | 40 (44.44%) | 3 (12% | 0.002* | 8 (36.36%) | 3 (13.64% | 0.077 |
| Stapled | 50 (55.56%) | 22 (88%) | 14 (63.64%) | 19 (86.36%) |
TLE thoracolaparoscopic esophagectomy, RALE robot assisted laparoscopic esophagectomy, BMI body mass index, ASA American Society of Anesthesiologists, GEJ gastroesophageal junction, SCC squamous cell carcinoma, AC adenocarcinoma, cT clinical T stage, cN clinical N stage, SD standard deviation
*Statistically significant
Operative and short-term oncological outcome parameters
| Parameter | TLE ( | RALE ( | TLEm ( | RALEm ( | ||
|---|---|---|---|---|---|---|
| Total LN | 23 ± 9.67 | 24.72 ± 8.97 | 0.426 | 22.73 ± 11.63 | 23.95 ± 8.23 | 0.688 |
| Duration (min) | 444 ± 61.39 | 525.40 ± 93.70 | < 0.001* | 444.77 ± 64.91 | 513.18 ± 91.23 | 0.006* |
| Blood loss (ml) | 139.39 ± 31.30 | 138.20 ± 31.72 | 0.867 | 133.18 ± 34.80 | 138.86 ± 31.20 | 0.572 |
| Hospital stay (days) | 14.09 ± 7.53 | 11.88 ± 6.06 | 0.180 | 12.73 ± 7.83 | 12.18 ± 6.35 | 0.801 |
| ICU stay (days) | 5.10 ± 4.61 | 4.60 ± 4.96 | 0.638 | 4.77 ± 4.81 | 4.91 ± 5.22 | 0.929 |
| Mortality | 2 (2.22%) | 0 | 0.320 | 1 (4.55%) | 0 | 0.235 |
TLE thoracolaparoscopic esophagectomy, RALE robot asssited laparoscopic esophagectomy, LN lymph node, ICU intensive care unit
*Statistically significant
Post operative complications and cost analyses
| Parameter | TLE ( | RALE ( | TLEm ( | RALEm ( | ||
|---|---|---|---|---|---|---|
| Pneumonia | 8 (8.89%) | 3 (12%) | 0.648 | 4 (18.18%) | 3 (13.64%) | 0.680 |
| RLN paresis | 7 (7.78%) | 3 (14.29%) | 0.533 | 1 (4.55%) | 3 (13.64%) | 0.306 |
| Chyle leak | 1 (1.11%) | 1 (4.76%) | 0.375 | 1 (4.55%) | 1 (4.55%) | 1.000 |
| Anastomotic leak | 3 (3.33%) | 0 | 0.222 | 1 (4.55%) | 0 | 0.235 |
| Clavien Dindo (> 3a) | 8 (8.89%) | 3 (12%) | 0.648 | 2 (9.09%) | 3 (13.64%) | 0.634 |
| Cost ($) | 4407.50 ± 570.36 | 5258.53 ± 431.67 | < 0.001* | 4243.01 ± 474.64 | 5271.75 ± 456.46 | < 0.001* |
TLE thoracolaparoscopic esophagectomy, RALE robot assisted laparoscopic esophagectomy, RLN recurrent laryngeal nerve, $ United States Dollars
*Statistically significant